114 Notes to the financial statements 12 Finance costs 2009 2008 2007 m m m Interest expense arising on: financial liabilities at amortised cost 790 664 313 derivatives at fair value through profit or loss 20 165 121 Fair value hedges: fair value adjustments on derivatives designated as hedging instruments 37 92 10 fair value adjustments on hedged items 38 90 8 Fair value adjustments on other derivatives at fair value through profit or loss 2 6 Reclassification of cash flow hedge from other comprehensive income 1 Unwinding of discounts on provisions 11 16 27 783 843 453 All derivatives at fair value through profit or loss except designated and effective hedging instruments are classified as held-for-trading financial instruments under IAS 39.
13 Associates and joint ventures 2009 2008 2007 m m m Associates: Share of after tax profits of Quest Diagnostics Inc. 73 47 48 Share of after tax profits of Aspen Pharmacare Holdings Limited 2 Share of after tax losses of other associates 3 3 3 72 44 45 Share of after tax losses profits of joint ventures 8 4 5 64 48 50 Share of turnover of joint ventures 13 13 13 Sales to joint ventures and associates 26 9 9 Summarised income statement information in respect of the Groups associates is set out below: 2009 2008 2007 m m m Total turnover: Quest Diagnostics Inc. 4,779 3,919 3,352 Aspen Pharmacare Holdings Limited 67 Others 7 3 4,853 3,922 3,352 Total profit: Quest Diagnostics Inc. 467 314 170 Aspen Pharmacare Holdings Limited 12 Others 14 7 3 465 307 167 The results of Aspen Pharmacare Holdings Limited included in the summarised income statement information above represent the estimated earnings of the Aspen group in the period since becoming an associated undertaking and are based on analysts forecasts.
GSK Annual Report 2009 Financial statements P91P182
